JP6653116B2 - オルメサルタンのプロドラッグ製剤 - Google Patents
オルメサルタンのプロドラッグ製剤 Download PDFInfo
- Publication number
- JP6653116B2 JP6653116B2 JP2014172328A JP2014172328A JP6653116B2 JP 6653116 B2 JP6653116 B2 JP 6653116B2 JP 2014172328 A JP2014172328 A JP 2014172328A JP 2014172328 A JP2014172328 A JP 2014172328A JP 6653116 B2 JP6653116 B2 JP 6653116B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- olmesartan medoxomil
- stearic acid
- olmesartan
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005480 Olmesartan Substances 0.000 title description 38
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 title description 38
- 229960005117 olmesartan Drugs 0.000 title description 38
- 239000000203 mixture Substances 0.000 title description 24
- 238000009472 formulation Methods 0.000 title description 13
- 229940002612 prodrug Drugs 0.000 title description 2
- 239000000651 prodrug Substances 0.000 title description 2
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims description 125
- 229960001199 olmesartan medoxomil Drugs 0.000 claims description 124
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims description 120
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 74
- 235000021355 Stearic acid Nutrition 0.000 claims description 72
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 72
- 239000008117 stearic acid Substances 0.000 claims description 72
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 41
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 39
- 239000008187 granular material Substances 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 37
- 239000004480 active ingredient Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 239000011230 binding agent Substances 0.000 claims description 20
- 239000007884 disintegrant Substances 0.000 claims description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- 239000000314 lubricant Substances 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 238000005550 wet granulation Methods 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 8
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 7
- 235000013539 calcium stearate Nutrition 0.000 claims description 7
- 239000008116 calcium stearate Substances 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 6
- 239000008120 corn starch Substances 0.000 claims description 6
- 229920001592 potato starch Polymers 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 152
- 230000000052 comparative effect Effects 0.000 description 73
- 238000012360 testing method Methods 0.000 description 42
- 238000002474 experimental method Methods 0.000 description 41
- 239000000047 product Substances 0.000 description 40
- 239000000126 substance Substances 0.000 description 39
- 238000003860 storage Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 22
- 239000002274 desiccant Substances 0.000 description 21
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 17
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 16
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 16
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000000654 additive Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 12
- 238000007922 dissolution test Methods 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 238000013112 stability test Methods 0.000 description 12
- 238000004513 sizing Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 8
- 229940127291 Calcium channel antagonist Drugs 0.000 description 8
- 244000269722 Thea sinensis Species 0.000 description 8
- 239000000480 calcium channel blocker Substances 0.000 description 8
- 239000002934 diuretic Substances 0.000 description 8
- 230000001882 diuretic effect Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- -1 (5-Methyl-2-oxo-1,3-dioxol-4-yl) methyl 4- (1-hydroxy-1-methylethyl) -2-propyl-1-[[2 ′-(1H-tetrazol-5 -Yl) biphenyl-4-yl] methyl] -1H-imidazole-5-carboxylate Chemical compound 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 238000013094 purity test Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229960000528 amlodipine Drugs 0.000 description 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 3
- 229950004646 azelnidipine Drugs 0.000 description 3
- 229960000772 camostat Drugs 0.000 description 3
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229960002003 hydrochlorothiazide Drugs 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 241000206601 Carnobacterium mobile Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940055053 benicar Drugs 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940112973 olmesartan medoxomil 10 mg Drugs 0.000 description 1
- 229940002493 olmesartan medoxomil 20 mg Drugs 0.000 description 1
- 229940029602 olmesartan medoxomil 40 mg Drugs 0.000 description 1
- 229940029603 olmesartan medoxomil 5 mg Drugs 0.000 description 1
- 229940043092 olmesartan medoxomil and amlodipine Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014172328A JP6653116B2 (ja) | 2014-08-27 | 2014-08-27 | オルメサルタンのプロドラッグ製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014172328A JP6653116B2 (ja) | 2014-08-27 | 2014-08-27 | オルメサルタンのプロドラッグ製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019089234A Division JP6765473B2 (ja) | 2019-05-09 | 2019-05-09 | オルメサルタンのプロドラッグ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016044170A JP2016044170A (ja) | 2016-04-04 |
| JP2016044170A5 JP2016044170A5 (enrdf_load_stackoverflow) | 2017-08-24 |
| JP6653116B2 true JP6653116B2 (ja) | 2020-02-26 |
Family
ID=55635052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014172328A Active JP6653116B2 (ja) | 2014-08-27 | 2014-08-27 | オルメサルタンのプロドラッグ製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6653116B2 (enrdf_load_stackoverflow) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI685483B (zh) | 2014-02-13 | 2020-02-21 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| RS59534B1 (sr) | 2014-02-13 | 2019-12-31 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| UA126277C2 (uk) | 2015-08-12 | 2022-09-14 | Інсайт Корпорейшн | Солі інгібітору lsd1 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| JP6765473B2 (ja) * | 2019-05-09 | 2020-10-07 | 日本ケミファ株式会社 | オルメサルタンのプロドラッグ製剤 |
| EP4059504A4 (en) * | 2020-01-16 | 2023-12-27 | Eisai R&D Management Co., Ltd. | LEMBOREXANT MEDICINAL COMPOSITION AND MEDICAL COMPOSITION CONTAINING SAME |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI367755B (en) * | 2005-05-20 | 2012-07-11 | Sankyo Co | Film coated product |
| US20070105923A1 (en) * | 2005-09-14 | 2007-05-10 | Glenmark Pharmaceuticals Limited | Substantially pure olmesartan medoxomil and processes for its preparation |
| EP1891952B1 (en) * | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Pharmaceutical composition of olmesartan medoxomil |
| BRPI0809161A2 (pt) * | 2007-03-23 | 2014-09-16 | Daiichi Sankyo Co Ltd | Olmesartan medoxomil, processos para a produção do mesmo, e, para a produção de um medicamento compreendendo olmesartan medoxomil, medicamento, e, uso de olmesartan medoxomil |
| WO2010018777A1 (ja) * | 2008-08-11 | 2010-02-18 | 第一三共株式会社 | におい抑制方法 |
| EP2387392B1 (en) * | 2008-12-30 | 2013-02-20 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of olmesartan |
| HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
| WO2011045760A2 (en) * | 2009-10-13 | 2011-04-21 | Ranbaxy Laboratories Limited | Micronized olmesartan medoxomil compositions |
| JP5680898B2 (ja) * | 2010-08-10 | 2015-03-04 | 京都薬品工業株式会社 | 苦味を抑制した速崩壊錠 |
| WO2014080365A1 (en) * | 2012-11-23 | 2014-05-30 | Ranbaxy Laboratories Limited | Method of reducing an unpleasant odor of a pharmaceutical composition |
-
2014
- 2014-08-27 JP JP2014172328A patent/JP6653116B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016044170A (ja) | 2016-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6653116B2 (ja) | オルメサルタンのプロドラッグ製剤 | |
| US20090281136A1 (en) | Prasugrel pharmaceutical formulations | |
| JP2019031576A (ja) | 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤 | |
| AU2013365715B2 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| TW201717937A (zh) | 含有芳基烷基胺化合物之醫藥組合物 | |
| EA015682B1 (ru) | Фармацевтическая композиция | |
| WO2014065390A1 (ja) | メントールウィスカーの析出を抑制する方法 | |
| EA028329B1 (ru) | Содержащая прасугрель стабильная фармацевтическая лекарственная форма с немедленным высвобождением для перорального введения, способ получения и применения | |
| WO2020090969A1 (ja) | 抗腫瘍剤を含む医薬組成物の包装体 | |
| US20130146496A1 (en) | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation | |
| JP6320260B2 (ja) | 医薬組成物 | |
| JP6765473B2 (ja) | オルメサルタンのプロドラッグ製剤 | |
| TWI689306B (zh) | 經安定化而成之醫藥組成物 | |
| KR20150115334A (ko) | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 | |
| PT2919815T (pt) | Uma composição farmacêutica contendo um inibidor eca e um bloqueador de canais de cálcio | |
| WO2005099698A1 (ja) | 安定化された４－アミノ－５－クロロ－Ｎ－［（１Ｒ，３ｒ，５Ｓ）－８－メチル－８－アザビシクロ［３．２．１］オクタ－３－イル]－２－［１－メチルブタ－２－インイルオキシ］ベンズアミド含有組成物 | |
| JP2017095441A (ja) | アジルサルタン含有医薬組成物、医薬組成物におけるアジルサルタンの安定化方法、及びアジルサルタンの安定化剤 | |
| JP2021098671A (ja) | レベチラセタム含有医薬組成物 | |
| JP6018420B2 (ja) | アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 | |
| JP6750785B2 (ja) | 安定なロスバスタチンカルシウム錠剤 | |
| JP2021116283A (ja) | エゼチミブおよびアトルバスタチン含有錠剤 | |
| JP6573098B2 (ja) | 安定なロスバスタチンカルシウム錠剤 | |
| WO2014188729A1 (ja) | 経口用組成物 | |
| CN103446072A (zh) | 帕洛诺司琼的固体药物组合物 | |
| HK40048975A (en) | Package for medical composition containing anti-tumor agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140828 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170712 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170712 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180522 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180720 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190108 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191122 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200127 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6653116 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |